Cancer Treatments Advisory Committee

This advisory committee meets regularly to discuss applications to fund cancer medicines and advise Pharmac on the application.

On this page

Latest update

29 April 2026

Provisional recommendations for March 2026 meeting
New page created

Members of the Cancer Treatments Advisory Committee

Prof Stephen Munn – Transplant Surgeon (Chair, PTAC Member)
Dr Matthew Strother – Medical Oncologist (PTAC Member)
Dr Scott Babington – Radiation Oncologist
Dr Oliver Brake – Haematologist
Prof Christopher Frampton – Biostatistician
Dr Richard Isaacs – Medical Oncologist
Dr Allanah Kilfoyle – Haematologist
Dr Vidya Mathavan – Haematologist
Dr Alice Minhinnick – Medical Oncologist
Dr Lochie Teague – Paediatric Haematologist / Oncologist
Dr Michelle Wilson – Medical Oncologist

2026 Committee meetings

Due to a high volume of funding applications, we have scheduled a series of meetings across 2026 for the Cancer Treatments Advisory Committee. These meetings will include both full-day and half-day sessions.

Agendas and provisional recommendations will be added as they are finalised.

Agenda for Thursday 30 April

Thursday 25 June
Friday 7 August
Thursday 17 September
Friday 6 November

More information about provisional recommendations

March 2026 CTAC meeting summary of provisional recommendations

Pharmaceutical and indication	Provisional recommendation
Pertuzumab and trastuzumab(external link) for the adjuvant treatment of HER2-positive early breast cancer at high risk of recurrence, within the context for treatments for malignancy, subject to Special Authority criteria	*Withheld
Pertuzumab and trastuzumab(external link) widened access for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer with an ECOG status score 2-3, within the context for treatments for malignancy, subject to Special Authority criteria	Medium priority
Belzutifan(external link) for the treatment of tumours associated with Von-Hippel Lindau disease, within the context for treatments for malignancy, subject to Special Authority criteria	Medium priority
Eltrombopag(external link) widened access for the first line treatment of severe aplastic anaemia in combination with immunosuppressive therapy, within the context for treatments for haematology, subject to Special Authority criteria	High priority
Eltrombopag(external link) widened access for the second-line treatment of relapsed/refractory severe aplastic anaemia in combination with immunosuppressive therapy, within the context for treatments for haematology, subject to Special Authority criteria	High Priority

*Withheld provisional recommendation – the applicant / supplier has requested the recommendation not be released until the full record is available.

Agenda for Friday 20 March

Summary of provisional recommendations of the 20 March CTAC meeting [PDF, 87 KB]

November 2025 CTAC meeting summary of provisional recommendations

Pharmaceutical and Indication	Provisional Recommendation
Abemaciclib(external link) for the adjuvant treatment of HR positive, HER2 negative early breast cancer, within the context of treatments for malignancy, subject to Special Authority criteria.	High priority
Ribociclib(external link) for the adjuvant treatment of HR positive, HER2 negative early breast cancer, within the context of treatments for malignancy, subject to Special Authority criteria.	Medium priority
Olaparib(external link) for the treatment of early high risk BRCA mutated HER2 negative breast cancer after neoadjuvant or adjuvant chemotherapy, within the context of treatments for malignancy, subject to special authority criteria.	High priority
Olaparib(external link) for the treatment of HER2 negative germline BRCA mutated metastatic breast cancer, within the context of treatments for malignancy, subject to Special Authority criteria.	Low priority
Olaparib(external link) for the treatment of HER2 negative PALB2 mutated metastatic breast cancer, within the context of treatments for malignancy, subject to Special Authority criteria.	Decline
Belantamab mafodotin(external link) for the treatment of relapsed or refractory multiple myeloma second line or later, within the context of treatments for malignancy, subject to Special Authority criteria.	High priority
Nivolumab(external link) (with chemotherapy) in the neoadjuvant setting for people with resectable non-small cell lung cancer, within the context of treatments for malignancy, subject to special authority criteria.	High priority